AquaBounty Technologies, Inc., recently got the green light from Canada’s environmental regulatory agency to commercially produce these eggs for its genetically engineered salmon at a hatchery on Prince Edward Island. Photo courtesy of AquaBounty.
A controversial genetically engineered salmon, known to its detractors as the “Frankenfish,” has moved a step closer to being sold on the U.S. market.
The “AquAdvantage” brand salmon is an Atlantic salmon that contains genetic material from Chinook salmon and ocean pout, an eel-like species. The genetically engineered salmon feeds year-round and therefore grows faster than conventional Atlantic salmon. It reaches market weight in a year and a half on 80 percent of the feed consumed by a conventionally farmed Atlantic salmon, according to the University of Missouri’s Kevin Wells, one of the scientists the FDA asked to evaluate the safety of the fish.
Environment Canada, as the Canadian environmental regulatory agency is known, gave the American company AquaBounty approval to produce eggs at the hatchery because scientists did not find them to be harmful to human or environmental health. The ruling by Canadian regulators does not allow the company to actually sell AquAdvantage salmon to the public.
“The decision to approve this was made by departmental scientists based on a thorough scientific evaluation of the latest evidence and studies,” Danny Kingsberry, an Environment Canada spokesman said in an email. “There are strict measures in place to prevent the release of this fish into the food chain.”
AquaBounty called the approval a “significant milestone” in its attempts to commercially produce the salmon, but said nothing had changed in its day-to-day business operations as a result of the announcement. The company still needs approval from the U.S. FDA to sell the AquAdvantage salmon in the U.S.
Currently, salmon eggs are being exported from the Prince Edward Island hatchery to a research and development facility in Panama where the fish are raised. AquaBounty says it will ask Panama’s government to commercially produce and process the salmon after it gets approval from the FDA.
“We remain hopeful that we will hear soon,” said Dave Conley, an AquaBounty spokesman. We began this process in 1995 and the FDA had a public meeting to share their review in 2010. We have provided everything that FDA has requested of us, and more. We have been open and transparent.”
The FDA, which regulates genetically engineered food, is still considering whether the salmon can be approved based on safety issues – including animal health, food safety, handler safety and production control and containment of the fish. Although the FDA closed its public comment period on AquaBounty’s application in April, an agency spokesperson said there was no set timeline for when a ruling would be issued.